Qyuns Therapeutics Launches Share Buyback as Board Deems Stock Undervalued

Qyuns Therapeutics Co., Ltd. Class H ( (HK:2509) ) just unveiled an update.

Qyuns Therapeutics has launched an on-market share repurchase program under a previously approved mandate, after its board concluded that the current share price significantly undervalues the company’s intrinsic worth and long‑term prospects. Between 6 November 2025 and 5 February 2026, the company repurchased approximately 2,487,800 shares, representing about 1.10% of its issued share capital, for a total consideration of roughly HK$50.75 million, with the shares to be held as treasury stock; the move is intended to bolster market confidence and enhance shareholder value, though future buybacks will remain subject to market conditions and board discretion, and the company has cautioned investors that there is no guarantee of further repurchases.

The most recent analyst rating on (HK:2509) stock is a Hold with a HK$22.00 price target. To see the full list of analyst forecasts on Qyuns Therapeutics Co., Ltd. Class H stock, see the HK:2509 Stock Forecast page.

More about Qyuns Therapeutics Co., Ltd. Class H

Qyuns Therapeutics Co., Ltd. is a biopharmaceutical company incorporated in the People’s Republic of China and listed in Hong Kong, focusing on the development and commercialization of therapeutic products. The company operates in the healthcare and life sciences sector and targets investors seeking exposure to innovative drug development and related medical technologies in the Chinese and broader Asian markets.

Average Trading Volume: 353,447

Technical Sentiment Signal: Buy

Current Market Cap: HK$4.65B

For detailed information about 2509 stock, go to TipRanks’ Stock Analysis page.